Volume 23, Issue 5 , Pages e133-e136, October 2010
Tamoxifen as First-line Treatment in a Premenarchal Girl with Juvenile Breast Hypertrophy
Abstract
Background
Juvenile breast hypertrophy is uncommon and is characterized by excessive breast enlargement in the peripubertal period. The clinical entity is thought to result from increased sensitivity of mammary tissue to normal levels of circulating hormones.
Case
Here, we report a female patient, aged 12 years and 6 months, suffering from juvenile breast hypertrophy, who presented at the third month of symptoms and benefited from tamoxifen treatment.
Comments
In experienced clinics, use of tamoxifen in the treatment of juvenile breast hypertrophy during the brisk growth period may become a medical alternative to reconstructive surgery.
Keywords: Juvenile breast hypertrophy, Tamoxifen, Adolescent, Selective estrogen receptor modulator
To access this article, please choose from the options below
PII: S1083-3188(09)00354-4
doi:10.1016/j.jpag.2009.11.003
© 2010 North American Society for Pediatric and Adolescent Gynecology. Published by Elsevier Inc. All rights reserved.
Volume 23, Issue 5 , Pages e133-e136, October 2010
